Growth Fund Announcement
Breakthrough Properties Growth Portfolio II is set to make significant strides as the company announces its initial closing.
On this occasion, Breakthrough Properties has successfully raised $430 million, marking a notable milestone for its Growth Portfolio II fund. This development comes at a time of expanding opportunities in the life science real estate sector.
Investment Strategy
Breakthrough Properties, known as a prominent joint venture between Tishman Speyer and Bellco Capital, aims to leverage this funding to diversify its portfolio of Class A life science properties across key innovation hubs globally.
This first closing amount reflects both direct investments and co-investor commitments, capitalizing on the successes of its previous $3 billion fund launched in 2022.
Current Market Environment
The market for life science real estate has presented an enticing landscape, with demand for high-quality facilities outpacing supply. The company’s strategy includes exploring various asset profiles and targeting attractive entry points where market fundamentals show promise.
Key Projects
Breakthrough Properties has already made its mark with notable developments like Torrey Heights in San Diego and One Helix in Amsterdam. These signature projects have attracted many leading companies in the life science sector, which speaks volumes about their quality and potential.
In fact, over 60 percent of their global portfolio is currently leased to top-tier investment-grade companies, including household names like Pfizer and AstraZeneca.
Future Prospects
As the firm looks ahead, it plans to undertake additional closings in 2026, reinforcing its commitment to expanding investments in prominent biopharma markets. The team at Breakthrough believes that current market dynamics present an exclusive opportunity to acquire assets at favorable pricing.
CEO Dan Belldegrun emphasized the firm’s optimistic outlook, pointing out how scientific advancement is accelerating and attracting interest even as generalist investors may step back. This unique period presents a ripe investment vintage for Breakthrough Properties.
Further insight from Tishman Speyer’s CEO Rob Speyer highlights the trust and credibility built with partners due to the success evidenced by the initial fund's performance.
Investment Approach
Breakthrough's Chief Investment Officer Dan D'Orazi reiterated that their investments will focus on Class A properties located in strategic locations, ensuring they stay ahead in terms of quality and market demand.
With the backing of both Tishman Speyer and Bellco Capital, Breakthrough has secured 70 percent of its leasing through pre-existing relationships with distinguished life science firms, showcasing the depth of its network and expertise.
Commitment to Sustainability
Beyond investments, Breakthrough Properties prioritizes creating environmentally conducive spaces. The company targets LEED Gold certification for its U.S. sites and BREEAM Outstanding ratings for projects in the U.K. and EU. This underscores their dedication to sustainability in the real estate sector.
Additionally, Breakthrough Properties has garnered recognition from industry benchmarks, ranking first among its peers in technology and science for their commitment to high-quality, sustainable research environments.
The firm aims to continue fostering innovation through a culture of collaboration, ensuring access to mentorship from its acclaimed Scientific Advisory Board alongside a vast venture capital network.
About Breakthrough Properties
Breakthrough Properties, established as a joint venture between Tishman Speyer and Bellco Capital, stands at the forefront of life science real estate. The firm's mission is to create environments that stimulate innovation and support advancements within biotechnology, agriculture, and nutrition.
By merging Tishman Speyer's extensive experience in global real estate with Bellco Capital's industry expertise, Breakthrough Properties aims to redefine how life-changing therapies are developed and delivered.
Frequently Asked Questions
What is Breakthrough Properties' main focus?
The company specializes in life science real estate development, aiming to create environments that foster innovation.
How much funding did Breakthrough Properties raise?
They raised $430 million for their Breakthrough Properties Growth Portfolio II fund.
What strategic locations does Breakthrough Properties target?
They focus on leading innovation clusters in the United States and Europe.
Who are some tenants of Breakthrough Properties?
Notable tenants include major companies like Pfizer, AstraZeneca, and Eli Lilly.
What sustainable certifications does Breakthrough Properties pursue?
They aim for LEED Gold certification in the U.S. and BREEAM Outstanding ratings in the U.K. and EU.
